These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27528501)

  • 21. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.
    Davi' MV; Dalle Carbonare L; Giustina A; Ferrari M; Frigo A; Lo Cascio V; Francia G
    Eur J Endocrinol; 2008 Nov; 159(5):533-40. PubMed ID: 18765561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.
    Berg C; Petersenn S; Lahner H; Herrmann BL; Buchfelder M; Droste M; Stalla GK; Strasburger CJ; Roggenbuck U; Lehmann N; Moebus S; Jöckel KH; Möhlenkamp S; Erbel R; Saller B; Mann K;
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3648-56. PubMed ID: 20463098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
    Giustina A; Bonadonna S; Bugari G; Colao A; Cozzi R; Cannavo S; de Marinis L; Degli Uberti E; Bogazzi F; Mazziotti G; Minuto F; Montini M; Ghigo E
    Eur J Endocrinol; 2009 Aug; 161(2):331-8. PubMed ID: 19465485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
    Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
    Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acromegaly: presentation, morbidity and treatment outcomes at a single centre.
    Anagnostis P; Efstathiadou ZA; Polyzos SA; Adamidou F; Slavakis A; Sapranidis M; Litsas ID; Katergari S; Selalmatzidou D; Kita M
    Int J Clin Pract; 2011 Aug; 65(8):896-902. PubMed ID: 21679284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
    Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
    J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acromegaly].
    Morange I; Jaquet P
    Rev Prat; 1996 Jun; 46(12):1482-5. PubMed ID: 8881161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing patterns in diagnosis and therapy of acromegaly over two decades.
    Nachtigall L; Delgado A; Swearingen B; Lee H; Zerikly R; Klibanski A
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2035-41. PubMed ID: 18381584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry.
    Fieffe S; Morange I; Petrossians P; Chanson P; Rohmer V; Cortet C; Borson-Chazot F; Brue T; Delemer B;
    Eur J Endocrinol; 2011 Jun; 164(6):877-84. PubMed ID: 21464140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
    Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The importance of early diagnosis in acromegaly].
    Valkusz Z; Tóth M; Boda J; Nagy E; Julesz J
    Orv Hetil; 2011 May; 152(18):696-702. PubMed ID: 21498157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea.
    Kim J; Hong N; Choi J; Moon JH; Kim EH; Hong JW; Lee EJ; Kim SG; Ku CR
    Eur J Endocrinol; 2023 Aug; 189(2):225-234. PubMed ID: 37548222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
    Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly.
    Colao A; Marek J; Goth MI; Caron P; Kuhn JM; Minuto FM; Weissman NJ
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2243-8. PubMed ID: 18381583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and treatment of acromegaly.
    Maugans TA; Coates ML
    Am Fam Physician; 1995 Jul; 52(1):207-13. PubMed ID: 7604764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test.
    Mazziotti G; Bonadonna S; Doga M; Patelli I; Gazzaruso C; Solerte SB; De Menis E; Giustina A
    Neuroendocrinology; 2008; 88(4):299-304. PubMed ID: 18617732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study.
    Chang SH; Wu LS; Lee CH; Kuo CT; Liu JR; Wen MS; Chen WJ; See LC; Yeh YH
    Int J Cardiol; 2015; 190():20-5. PubMed ID: 25912112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues.
    Tzanela M; Vassiliadi DA; Gavalas N; Szabo A; Margelou E; Valatsou A; Vassilopoulos C
    Clin Endocrinol (Oxf); 2011 Jul; 75(1):96-102. PubMed ID: 21521267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.